Skip to main content

Advertisement

Table 2 Correlation between Braf/p300 staining and AJCC stage in 327 melanoma patients

From: A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma

  Stage I Stage II Stage III Stage IV p-value*
Braf      
Low 37 (46.3%) 26 (23.0%) 11 (20.0%) 20 (25.3%) 9.8 × 10-4
High 43 (53.8%) 87 (77.0%) 44 (80.0%) 59 (74.7%)  
Nuclear p300      
Low 29 (36.3%) 47 (41.6%) 30 (54.5%) 33 (41.8%) 0.204
High 51 (63.7%) 66 (58.4%) 25 (45.5%) 46 (59.2%)  
Cytoplasmic p300      
Low 48 (60.0%) 53 (46.9%) 17 (30.9%) 36 (45.6%) 0.011
High 32 (40.0%) 60 (53.1%) 38 (69.1%) 43 (54.4%)  
Braf and nuclear p300      
Low braf low p300 11 (13.8%) 13 (11.5%) 6 (10.9%) 6 (7.6%) 0.010
Low braf high p300 26 (32.5%) 14 (12.4%) 6 (10.9%) 16 (20.3%)  
High braf low p300 18 (22.5%) 34 (30.1%) 24 (43.6%) 27 (34.2%)  
High braf high p300 25 (31.3%) 52 (46.0%) 19 (34.6%) 30 (38.0%)  
Braf and cytoplasmic p300      
Low braf low p300 21 (26.3%) 19 (16.8%) 5 (9.1%) 7 (8.8%) 8.7 × 10-5
Low braf high p300 16 (20.0%) 7 (6.2%) 6 (10.9%) 13 (16.5%)  
High braf low p300 27 (33.7%) 34 (30.1%) 12 (21.8%) 29 (36.7%)  
High braf high p300 16 (20.0%) 53 (46.9%) 32 (58.2%) 30 (38.0%)  
  1. *- χ2 test.